神经保护性帕金森病治疗:过渡金属二甲基化物纳米花治疗缓解病态细胞应激应激
Charles L Mitchell1,2, Mikhail Matveyenka2, Harris C Brown2
1Interdisciplinary Program in Genetics and Genomics, Texas A&M University, College Station, Texas, USA.
bioRxiv : the preprint server for biology
|November 19, 2025
概括
二硫化物和二化物纳米花通过清除α-synuclein聚合物和恢复线粒体功能,对帕金森病产生神经保护作用. 这些纳米材料显著增加了C. elegans模型的寿命,表明了治疗潜力.
科学领域:
- 纳米材料科学 科学 纳米材料科学
- 神经科学是一个神经科学.
- 生物化学 生化学
背景情况:
- 帕金森病 (PD) 涉及多巴胺基神经元退化,与α-syn聚合和线粒体功能障碍有关.
- 过渡金属二甲基化物 (TMD) 纳米花 (NFs) 显示出通过生物生成恢复线粒体健康的潜力.
- 在PD中,TMD NFs的治疗应用在很大程度上尚未被探索.
研究的目的:
- 为了研究二硫化物 (MoS2) 和二化物 (MoSe2) 纳米花 (NFs) 对α-syn毒性的神经保护作用.
- 评估TMD NFs对细胞过程的影响,如未展开的蛋白质反应 (UPR),自和线粒体功能.
- 在C. elegans的PD模型中评估TMD NF的疗效.
主要方法:
- 用α-syn聚合物和TMD NF (MoS2和MoSe2) 处理培养的神经元和星体细胞.
- 评估UPR,自,外细胞分裂,线粒体损伤,线粒体生物发生和活性氧物种 (ROS) 水平.
- 向α-syn过度表达的C. elegans注射TMD NF,并评估α-syn聚合和寿命.
主要成果:
- MoS2和MoSe2 NF抑制了α-syn诱导的UPR,并增强了α-syn纤维的自和异细胞形成.
- TMD NFs逆转了α-syn诱导的线粒体损伤,刺激了线粒体生物发生,并降低了ROS水平.
- TMD NFs完全从α-syn细胞毒性中拯救了神经元和星细胞,并通过减少α-syn聚合,显著增加了C. elegans的寿命.
结论:
- 在体外和体内,MoS2和MoSe2NF对α-syn毒性具有显著的神经保护性.
- TMD NFs通过准帕金森病的关键病理机制,提供了一种新的治疗策略.
- 这些发现表明TMD NFs是减缓PD进展的有希望的候选人.
相关概念视频
Parkinson's Disease: Treatment
953
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
953
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Alzheimer's Disease: Treatment
772
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
772

